A recent trial suggests that Bristol-Myers Squibb’s daclatasvir plus Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, cures high rates of people with genotype 1 of hepatitis C virus (HCV), including those with cirrhosis. Preliminary results from the trial were reported at the 50th International Liver Congress in Vienna, Austria.
Continue reading at: hepmag.com/articles/daclata...